Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers

BACKGROUND. The frequency with which targeted tumor sequencing results will lead to implemented change in care is unclear. Prospective assessment of the feasibility and limitations of using genomic sequencing is critically important. METHODS. A prospective clinical study was conducted on 100 patient...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Oncologist
Main Authors: Hirshfield, Kim M., Tolkunov, Denis, Zhong, Hua, Ali, Siraj M., Stein, Mark N., Murphy, Susan, Vig, Hetal, Vazquez, Alexei, Glod, John, Moss, Rebecca A., Belyi, Vladimir, Chan, Chang S., Chen, Suzie, Goodell, Lauri, Foran, David, Yelensky, Roman, Palma, Norma A., Sun, James X., Miller, Vincent A., Stephens, Philip J., Ross, Jeffrey S., Kaufman, Howard, Poplin, Elizabeth, Mehnert, Janice, Tan, Antoinette R., Bertino, Joseph R., Aisner, Joseph, DiPaola, Robert S., Rodriguez-Rodriguez, Lorna, Ganesan, Shridar
פורמט: Artigo
שפה:Inglês
יצא לאור: AlphaMed Press 2016
נושאים:
Cancer Diagnostics and Molecular Pathology
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5189630/
https://ncbi.nlm.nih.gov/pubmed/27566247
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0049
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים